<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137878">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01927081</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00044446</org_study_id>
    <nct_id>NCT01927081</nct_id>
  </id_info>
  <brief_title>Self-management Interventions for Advanced Breast Cancer</brief_title>
  <official_title>Self-management Interventions for Pain in Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Alternative Medicine (NCCAM)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate whether self-management discussion groups
      are helpful for women with advanced breast cancer who are experiencing pain. The study is
      looking at the usefulness of two different types of discussion groups, one of which also
      includes gentle exercise.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Feasibility</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Feasibility will be indicated by our ability to meet accrual goals, and by at least 70% of patients attending ≥7 of 8 sessions and providing post-test assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Acceptability will be assessed via participant ratings on a standardized measure of treatment effectiveness/satisfaction, supplemented by exit interview</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pain</measure>
    <time_frame>study entry, following completion of the intervention (approximately 3 months), 6 months, and 9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>pain intensity as assessed by the Brief Pain Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fatigue</measure>
    <time_frame>study entry, following completion of the intervention (approximately 3 months), 6 months, and 9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fatigue as assessed by the Brief Fatigue Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sleep disturbance</measure>
    <time_frame>study entry, following completion of the intervention (approximately 3 months), 6 months, and 9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sleep disturbance as assessed by the Pittsburgh Sleep Quality Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Psychological distress</measure>
    <time_frame>study entry, following completion of the intervention (approximately 3 months), 6 months, and 9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anxiety and depression assessed using the Hospital Anxiety and Depression Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functional capacity</measure>
    <time_frame>study entry, following completion of the intervention (approximately 3 months), 6 months, and 9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Functional capacity assessed using a 6-minute walk test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>discussion group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eight weekly group sessions in which participants will engage in discussions regarding issues related to coping with advanced cancer and pain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>discussion group + exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eight weekly group sessions in which participants will engage in discussions regarding issues related to coping with advanced cancer and pain and learn gentle exercise and breathing techniques</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>discussion group</intervention_name>
    <description>Participants engage in discussions regarding issues related to coping with advanced cancer and pain</description>
    <arm_group_label>discussion group</arm_group_label>
    <arm_group_label>discussion group + exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>gentle exercise</intervention_name>
    <description>Patients learn gentle exercise and breathing techniques</description>
    <arm_group_label>discussion group + exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of Stage IV breast cancer or recurrent metastatic breast cancer,

          -  receiving care at Duke Cancer Institute,

          -  life expectancy ≥9 months as estimated by the treating oncologist,

          -  usual pain rating over the past 2 weeks of at least 3 on a 0-10 scale,

          -  speak and read English,

          -  be at least age 18

        Exclusion Criteria:

          -  cognitive impairment as assessed by the 6-item Mini-mental Status Exam,

          -  Karnofsky Performance Rating of &lt;60 as rated by the oncology provider,

          -  metastases to the brain,

          -  treatment for serious psychiatric illness (e.g., schizophrenia, severe depression) in
             the past 6 months,

          -  currently engaged in yoga practice ≥ 1 day per week
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Porter, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessyka Glatz, MA</last_name>
    <phone>919-416-3434</phone>
    <email>glatz001@mc.duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 14, 2014</lastchanged_date>
  <firstreceived_date>August 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
